Trial ID or NCT#

NCT03707080

Status

recruiting iconRECRUITING

Purpose

This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.

Official Title

DAA-PASS: A Post-Authorisation Safety Study of Early Recurrence of Hepatocellular Carcinoma in HCV-Infected Patients After Direct-Acting Antiviral Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul Kwo
Paul Kwo
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology)

Contact us to find out if this trial is right for you.

CONTACT

Swati Toppo
(650) 497-4151